Institute for Genomic Medicine Project Aims to Find Candidate Treatments for Alternating Hemiplegia of Childhood
Online PR News – 07-December-2015 – Cure AHC, Inc. has awarded a grant of $75,000 to Columbia University Institute for Genomic Medicine (IGM) for the Multiple Electrode Array (MEA) Compound Screening Project with Optogenetics for Alternating Hemiplegia of Childhood (AHC) Mouse Model. The Project will enable the team to rapidly screen a wide array of compounds to test the potential for efficacy, and at the same time gain deeper understanding of the molecular and cellular functions and malfunctions at work in the disease. It will also help provide rich data on efficacy when and if candidate compounds are identified, or point the way for development of new compounds. It will also help more consistently produce the conditions of the episodic nature of AHC, for more accurate and consistent research results.
We are hopeful that this project will fill in some key gaps in knowledge about AHC and propel us forward with candidates for treatment, said Erin Heinzen, PhD, Deputy Director of the Institute for Genomic Medicine (and Project Leader) and Assistant Professor of Pathology and Cell Biology at Columbia University Medical Center.
Cure AHC recognizes the strategic nature of this important work at the IGM, and applauds this collaborative effort that augments our previous research investments said Cure AHC Co-Founder and President Jeff Wuchich. Cure AHC has also launched its 2015 End of Year Global $30,000 Challenge Grant Campaign, with plans to fund several other collaborative and complementary research projects in 2016.
Alternating Hemiplegia of Childhood (AHC) is an incurable, rare and painful neurological disorder that causes episodes of temporary paralysis that last minutes or even days. AHC is often mistaken for cerebral palsy or epilepsy, which impairs the ability to learn and communicate. AHC also affects muscle control, causing shallow breathing and difficulty walking and swallowing. Researchers discovered the gene that causes Alternating Hemiplegia of Childhood (AHC) in 2012 and they continue to make progress in their understanding of the disease, which aids in better treatment and ultimately a cure for AHC sufferers, as well as potential benefit to more common diseases such as epilepsy, stroke, and heart disease.
Cure AHC is a 501 (c) 3 Non-profit organization that was created to raise awareness and research funds to develop a treatment and discover the cure for Alternating Hemiplegia of Childhood. Please visit http://bit.ly/CureAHCAM560 for Chicago Radio Station Interview Recording. Donations to Cure AHC can be made online through the www.cureahc.org or a check may be sent to Cure AHC, Inc. at 545 Irina Drive, Rolesville, NC 27571. For more information about Alternating Hemiplegia of Childhood (AHC) please visit www.cureahc.org or contact email@example.com.
“Cure AHC recognizes the strategic nature of this important work at the IGM, and applauds this collaborative effort that augments our previous research investments.”